ALT stock sentiment todayAltimmune, Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
ALT
Altimmune, Inc.A high-risk, high-reward GLP-1 underdog facing a massive 'funding vs. efficacy' gap compared to big pharma leaders.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ALT. Not financial advice.
Price · last 12 months
Gossip
The narrative centers on pemvidutide's potential as a 'cleaner' weight loss drug due to superior lean mass preservation, though recent price action reflects exhaustion and skepticism over partnership prospects.
- ·Speculation regarding a potential buyout or partnership with Big Pharma
- ·Superiority claims in muscle mass preservation compared to Wegovy/Zepbound
- ·Fear of further dilution as cash runway remains a concern for Phase 3 trials
Financial
Altimmune is a clinical-stage biotech with no revenue and high R&D burn; while the balance sheet has enough cash for near-term operations, a Phase 3 trial for obesity will require significant capital infusion or a partner.
- ·Cash and equivalents: ~$140M (as of last major filing)
- ·Zero product revenue; primary income from interest/grants
- ·Net loss consistently exceeding $80M annually
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Institutions added more shares than they cut last quarter.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Clinical trial failure in upcoming Phase 2b/3 readouts
- ·Extreme share dilution if no partner is secured by 2025
- ·Dominance of Eli Lilly and Novo Nordisk squeezing out niche competitors
Peer temperature
How direct competitors stack up against ALT right now.
- HOTVKTXViking Therapeutics
HOTTER — stronger clinical data for VK2735 and a significantly higher market valuation reflecting lower execution risk.
See full analysis → - HOTLLYEli Lilly
HOTTER — established market dominance with Zepbound and massive cash flows that ALT lacks for commercialization.
See full analysis → - NEUTRALTERNTerns Pharmaceuticals
SIMILAR — also chasing the oral GLP-1 market but currently lacks the lean-mass preservation narrative that gives ALT its speculative edge.
See full analysis →
- ALT-24.3%
- VKTX-8.4%
- LLY+23.4%
- TERN—
Analyst price target
Consensus average of 6 analysts · median 20.00
Source: StockAnalysis.com · updated 2026-10-09
AI-generated analysis for informational purposes only. Not financial advice.